Skip to main content

Table 2 Associations between baseline plasma lnMMP-1, -2, -3, -9 and -10 and lnTIMP-1 and incident cardiovascular disease (n = 86)

From: Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

Model MMP-1 MMP-2 MMP-3 MMP-9 MMP-10 TIMP-1
HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value
1 1.51 1.20; 1.91 <0.001 1.65 1.28; 2.13 <0.001 1.47 1.13; 1.92 0.004 1.44 1.17; 1.78 0.001 1.20 0.97; 1.50 0.101 1.87 1.40; 2.49 <0.001
2 1.26 1.00; 1.60 0.054 1.49 1.11; 1.99 0.007 1.16 0.88; 1.53 0.308 1.24 0.99; 1.55 0.058 1.03 0.82; 1.29 0.801 1.33 0.95; 1.87 0.100
3 1.23 0.96; 1.59 0.103 1.34 0.96; 1.85 0.085 0.99 0.73; 1.34 0.991 1.21 0.96; 1.52 0.112 0.91 0.71; 1.16 0.440 1.03 0.72; 1.49 0.858
4 1.23 0.97; 1.55 0.094 1.47 1.11; 1.96 0.008 1.15 0.87; 1.52 0.321 1.18 0.93; 1.48 0.173 1.02 0.81; 1.28 0.890 1.23 0.87; 1.75 0.243
5 1.28 1.01; 1.63 0.043 1.48 1.11; 1.98 0.008 1.16 0.88; 1.54 0.284 1.24 1.00; 1.55 0.055 1.03 0.82; 1.29 0.799 1.32 0.94; 1.87 0.111
  1. HR, hazard ratio for incident cardiovascular disease per 1 SD increase in lnMMP-1, -2, -3, -9 or -10 or lnTIMP-1, MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
  2. Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
  3. Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline
  4. Model 3 Model 2 + eGFR and Ln-UAE
  5. Model 4 Model 2 + inflammatory z-score
  6. Model 5 Model 2 + endothelial dysfunction z-score